Free Trial

BrainsWay Q2 2024 Earnings Report

BrainsWay logo
$10.23 -0.09 (-0.87%)
As of 01/17/2025 04:00 PM Eastern

BrainsWay EPS Results

Actual EPS
$0.04
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
-$0.05

BrainsWay Revenue Results

Actual Revenue
$10.01 million
Expected Revenue
$9.40 million
Beat/Miss
Beat by +$610.00 thousand
YoY Revenue Growth
N/A

BrainsWay Announcement Details

Quarter
Q2 2024
Time
Before Market Opens

Conference Call Resources

Conference Call Audio

BrainsWay Earnings Headlines

Brainsway reports independent pilot data on Deep TMS technology for AUD
Do this Before Elon’s Reveal on January 22nd
Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.
Brainsway announces publication on pain reduction with Deep TMS therapy
See More BrainsWay Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BrainsWay? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BrainsWay and other key companies, straight to your email.

About BrainsWay

BrainsWay (NASDAQ:BWAY) develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

View BrainsWay Profile

More Earnings Resources from MarketBeat